Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell entities : Allovir, inc. save search
AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy
Published: 2023-12-22 (Crawled : 12:00) - globenewswire.com
ALVR | $0.7952 4.22% 4.05% 280K
|
Health Technology
|
| O: -67.32%
H: 7.03%
C: 0.51%
cell program therapy
AlloVir Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific T Cell Therapy, for the Treatment of BK Viremia in Kidney Transplant Recipients
Published: 2022-06-07 (Crawled : 13:20) - biospace.com/
ALVR | $0.7952 4.22% 4.05% 280K
|
Health Technology
|
| O: -1.55%
H: 7.85%
C: 4.71%
treatment ongoing kidney
FDA Grants Orphan Drug Designation (ODD) to AlloVir’s Posoleucel, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T-Cell Therapy, for the Treatment of Virus-Associated Hemorrhagic Cystitis
Published: 2021-10-04 (Crawled : 12:00) - biospace.com/
ALVR | $0.7952 4.22% 4.05% 280K
|
Health Technology
|
| O: 6.01%
H: 0.0%
C: -13.5%
treatment fda orphan drug therapy drug t-cell tollovir designation
Data Presented at IDWeek™ 2021 Demonstrate that ALVR109, AlloVir’s Investigational SARS-CoV-2-Specific T Cell Therapy, Is Reactive Against a Broad Range of Variants, Including Delta
Published: 2021-09-29 (Crawled : 12:00) - biospace.com/
ALVR | $0.7952 4.22% 4.05% 280K
|
Health Technology
|
| O: 1.46%
H: 2.47%
C: -0.76%
therapy sars-cov-2 t-cell
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.